Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Astex Therapeutics receives IND approval for AT13387

Astex Therapeutics receives IND approval for AT13387

15th February 2008

Astex Therapeutics has received approval of its Investigational New Drug (IND) application for AT13387 from the US Food and Drug Administration.

The selective small molecule inhibitor of Heat Shock Protein 90 is used to treat cancer and is the third IND candidate from Astex’s internal discovery and development programmes to be approved.

Clinical trials of AT13387 in cancer patients are scheduled for 2008.

Preclinical data for the drug showing its efficacy in tumour models was presented at the American Association for Cancer Research’s annual meeting in April 2007.

Harren Jhoti, chief executive officer of Astex, said: "I am delighted that we have received our third IND approval in as many years.

"This approval is a great achievement and a testament to the productivity of our fragment-based drug discovery platform and keeps us on target to deliver at least one IND candidate per year."

Meanwhile, Astex has also revealed that Novartis is planning to extend its drug discovery alliance with Astex in a bid to develop novel cell cycle control drugs for the treatment of cancer.
ADNFCR-1050-ID-18469336-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.